Naloxone

Emergent BioSolutions Continues to Broaden Access, Awareness and Availability of NARCAN® Nasal Spray to Help Save Lives from the Ongoing Opioid Crisis

Retrieved on: 
Thursday, March 28, 2024
FSA, U.S. FDA, Arm, Heroin, Risk, Education, Pharmacy, School, Naloxone, Policy, EBS, Flexible, House, Drug, OTC, CDC, Restaurant, Medicaid, National Safety Council, AED, HSA, FDA, Emergent BioSolutions, NSC, Medicine, Fentanyl, Pharmaceutical industry

Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans.

Key Points: 
  • Emergent and other stakeholders in the fight must continue raising awareness about the availability of products like NARCAN® Nasal Spray, reducing stigma and further improving access for all Americans.
  • Since the OTC launch, NARCAN® Nasal Spray can be purchased at more than 32,000 mass drug, grocery, online retailers and e-commerce sites.
  • Emergent is working with retail partners to make it easy to find and access, however each retailer ultimately determines in-store product placement.
  • “That’s why we remain committed to increasing awareness of NARCAN® Nasal Spray availability.

FDA Accepts Filing of New Drug Application for Nalmefene Auto-injector for the Treatment of Known or Suspected Opioid Overdose

Retrieved on: 
Monday, April 8, 2024
General Health, FDA, Health, Pharmaceutical, Medical Supplies, Hypoventilation, Hypersensitivity, Nalmefene, Pulmonary edema, Caregiver, Safety, Tachycardia, Risk, New Drug Application, Patient, Ventricular tachycardia, Naloxone, Health care, Buprenorphine, Mortality, NDA, MD, Methadone, Ventricular fibrillation, Hypotension, Oxygen, LAAM, Recurrence, Allergy, Purdue University, Hypertension, Fentanyl, Pharmaceutical industry

Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.

Key Points: 
  • Purdue Pharma L.P. (“Purdue”) announced today that FDA has accepted for filing the company’s New Drug Application (NDA) for the auto-injector delivery form of nalmefene hydrochloride injection*.
  • "Through this auto-injector FDA submission, our goal is to help expand the availability of nalmefene to the community alongside existing available options for healthcare professionals.
  • Priority review status means that FDA will expedite the review process to evaluate a drug that would significantly improve treatment of a serious condition.
  • Nalmefene Hydrochloride Injection is indicated in the management of known or suspected opioid overdose.

Purdue Pharma L.P. Awards Grant for Investigator-initiated Research to Examine Opioid Overdose Reversal Using Nalmefene HCl Injection

Retrieved on: 
Wednesday, March 27, 2024
Other Health, Research, General Health, Pharmaceutical, University, Education, Clinical Trials, Science, Biotechnology, FDA, Other Science, Health, Hypoventilation, Hypersensitivity, Nalmefene, IIR, Pulmonary edema, Doctor of Pharmacy, University of New Mexico, Safety, Tachycardia, Risk, Patient, Hydrogen chloride, Purdue Pharma, Naloxone, UNM, Emergency medicine, Ventricular tachycardia, Mortality, Buprenorphine, MD, Methadone, Emergency department, Ventricular fibrillation, Hypotension, Oxygen, HCI, ED, Hypertension, Recurrence, LAAM, Opioid overdose, Purdue University, Pharmaceutical industry

“We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”

Key Points: 
  • “We are enthusiastic about supporting research that can contribute to addressing the opioid overdose crisis.”
    The prospective, randomized study, “Evaluation of Nalmefene HCl Injection for Recurrent Respiratory Depression After Suspected Acute Opioid Overdose in an Emergency Department,” will compare the efficacy and safety of nalmefene HCl injection to naloxone injection in the treatment of recurrent respiratory depression due to opioid overdose.
  • Nalmefene HCl injection is an opioid antagonist indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids and in the management of known or suspected opioid overdose.
  • Nalmefene Hydrochloride injection is contraindicated in patients with a known hypersensitivity to the product.1 The Company distributes nalmefene HCl injection for no profit.
  • The study will be independently developed and carried out by UNM’s research team with Purdue Pharma providing only funding and nalmefene HCI injection.

Joint Statement from the Co-Chairs of the Special Advisory Committee on the Epidemic of Opioid Overdoses - Latest National Data on Substance-Related Harms

Retrieved on: 
Wednesday, March 27, 2024
Consciousness, Risk, Opioid, COVID-19, Patient, Benzodiazepine, Ageing, Inhalation, Public, Naloxone, Portrait, Epidemic, Male, Special Advisory Committee, Xylazine, Government, Fentanyl, Pharmaceutical industry

These numbers are the largest observed since data collection  began in 2016, signifying the ongoing worsening of this urgent public health crisis.

Key Points: 
  • These numbers are the largest observed since data collection  began in 2016, signifying the ongoing worsening of this urgent public health crisis.
  • These latest data show that in Canada between January and September 2023, there were 5,975 apparent opioid-related deaths and 4,646 hospitalizations for opioid-related poisonings.
  • New data from emergency departments (ED) show that during the same period, there were 21,708 reported opioid poisoning ED visits, which is 80 per day.
  • While it may take time to see results, everything we do to help combat this crisis and save lives is critical.

NECA Passionately Supports White House Challenge to Save Lives from Overdose

Retrieved on: 
Wednesday, March 13, 2024
Health, Employment, Challenge, Organization, Air conditioning, White, NECA, Naloxone, MCAA, National Electrical Contractors Association, The Challenge, SMACNA, Safety, Workforce, National Association, Sheet metal

WASHINGTON, March 13, 2024 /PRNewswire/ -- The National Electrical Contractors Association (NECA) is aligned with the Biden Administration's nationwide initiative to beat the overdose crisis in the United States, through the " White House Challenge to Save Lives from Overdose " program launched Wednesday, March 13, 2024.

Key Points: 
  • WASHINGTON, March 13, 2024 /PRNewswire/ -- The National Electrical Contractors Association (NECA) is aligned with the Biden Administration's nationwide initiative to beat the overdose crisis in the United States, through the " White House Challenge to Save Lives from Overdose " program launched Wednesday, March 13, 2024.
  • "The Challenge is a nationwide call-to-action to stakeholders across all sectors to save lives by committing to increase training on and access to lifesaving opioid overdose reversal medications," the White House explained in a statement released on Wednesday.
  • While working with a White House fellow to provide our support and encouragement of this important initiative, NECA is one of several organizations and businesses to promote this call-to-action.
  • The introduction of the "White House Challenge to Save Lives from Overdose" initiative is a step towards addressing this crisis.

Combatting Overdoses: The SPOT's Mission to Prevent Spring Break Deaths

Retrieved on: 
Tuesday, March 12, 2024
Heroin, Xylazine, HIV, Risk, COVID-19, Naloxone, Hope, Fentanyl, Syringe, STI, Accidental, Drug, CDC, Safety, SPOT, HCV, Pharmaceutical industry

Emelina Martinez, Safe Syringe Exchange Services Manager for The SPOT, states, "Many spring breakers don't realize that the substances they are purchasing on the street might be laced with fentanyl or xylazine.

Key Points: 
  • Emelina Martinez, Safe Syringe Exchange Services Manager for The SPOT, states, "Many spring breakers don't realize that the substances they are purchasing on the street might be laced with fentanyl or xylazine.
  • Our goal is to reach more people this year, distributing more Narcan with the hope of saving even more lives."
  • This emphasizes the critical need for awareness and harm reduction efforts, such as those undertaken by The SPOT, to mitigate the negative consequences of substance use during spring break and beyond.
  • In addition to its primary mission of harm reduction, The SPOT operates as a mobile medical clinic, offering a range of free medical services.

Methamphetamine Use Reaches All-Time High in People Who Use Fentanyl with No Signs of Slowing, Adding Fuel to U.S. Fentanyl Crisis

Retrieved on: 
Wednesday, February 21, 2024
Health, Other Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Fentanyl, Collection, Heroin, Cocaine, CPE, Multimedia, Xylazine, Evolution, Naloxone, Drug, Doctor of Pharmacy, UDT, Methamphetamine, ETI, Patient, Drug overdose, Ageing

View the full release here: https://www.businesswire.com/news/home/20240220752791/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20240220752791/en/
    Shifting trends in the co-detection of prescription opioids, heroin, methamphetamine, and cocaine nationally provide insight into how each has changed over time.
  • More recently, a fourth wave of overdose deaths co-involving fentanyl with stimulants like methamphetamine and cocaine has emerged.
  • Stimulants were co-involved in over 30% of fentanyl overdose deaths in 2021, up from less than 1% in 2010.
  • Millennium Health’s Signals Report shows that UDT data tightly correlate with U.S. overdose mortality rates and closely follow the evolution of America’s fentanyl crisis.

ASTHO Appoints Joseph Kanter, MD, MPH, as New Chief Executive Officer

Retrieved on: 
Monday, March 4, 2024
LDH, Multimedia, Addiction, City, Naloxone, MBA, Sound, Health, COVID-19, History, Tulane University, Public, Policy, MPH, Medicine, Health equity, Homelessness, State, Infection, Environment, Partnership, Nursing

ARLINGTON, Va., March 4, 2024 /PRNewswire/ -- The Association of State and Territorial Health Officials (ASTHO) today announced that Joseph Kanter, MD, MPH, has been named as the organization's chief executive officer, effective April 8, 2024.

Key Points: 
  • ARLINGTON, Va., March 4, 2024 /PRNewswire/ -- The Association of State and Territorial Health Officials (ASTHO) today announced that Joseph Kanter, MD, MPH, has been named as the organization's chief executive officer, effective April 8, 2024.
  • Dr. Kanter, a board-certified emergency physician, brings a wealth of experience to ASTHO including prior public service as both a Louisiana state health officer and municipal health director.
  • Dr. Kanter joins ASTHO from the Louisiana Department of Health (LDH) where he served as state health officer and medical director from January 2021 - February 2024.
  • ASTHO members, the chief health officials of these jurisdictions, are dedicated to formulating and influencing sound public health policy and to ensuring excellence in public health practice.

Hikma hosts White House Drug Policy Director Dr. Rahul Gupta at its Columbus, Ohio manufacturing facility

Retrieved on: 
Wednesday, February 21, 2024
Black, Naloxone, Government, ONDCP, Administration, Organization, Patient, Science, Public

COLUMBUS, Ohio, Feb. 21, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.

Key Points: 
  • COLUMBUS, Ohio, Feb. 21, 2024 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today welcomed Dr. Rahul Gupta, Director of the White House Office of National Drug Control Policy (ONDCP), to its Columbus, Ohio manufacturing facility for a visit and important dialogue on the US opioid overdose epidemic and Hikma's and ONDCP's shared goal of expanding the availability and awareness of life-saving naloxone.
  • During the visit, Dr. Gupta met with Hikma employees and toured the Columbus facility, observing firsthand the production of Hikma's overdose reversal medicine KLOXXADO® (naloxone HCl) nasal spray 8mg.
  • "In his Unity Agenda, President Biden set a clear directive: we must all come together to address the nation's overdose epidemic," said White House Office of National Drug Control Policy (ONDCP) Director Dr. Rahul Gupta.
  • "Hikma firmly believes that no one who needs overdose reversal medicine should lack access because of costs, awareness or availability.

Nitazenes are a powerful class of street drugs emerging across the US

Retrieved on: 
Thursday, February 15, 2024
Fentanyl, ISO, Virginia School for Girls, Pharmacology, Justice minister, Toxicology, Cocaine, Heroin, Schedule, Drug, Food, Pediatrics, DEA, Naloxone, Emergency medicine, Conversation, Death, Risk, Pharmacy, University, Ground substance, Morphine, Benzimidazole, Blue, Research, Human, Controlled Substances Act

Researchers have relatively little information on how the human body reacts to nitazenes because the drugs have never gone through clinical trials.

Key Points: 
  • Researchers have relatively little information on how the human body reacts to nitazenes because the drugs have never gone through clinical trials.
  • As law enforcement has cracked down on other drugs such as fentanyl, illegal labs have used historical pharmacology research to formulate analogs of nitazenes as street drugs.
  • Although nitazenes are now identified as illegal street drugs in numerous countries, many medical providers aren’t even aware they exist.
  • Nitazenes are also mixed with other street drugs such as heroin and fentanyl and with fake oxycodone pills, without users knowing it.